Nowecki, Zbigniew

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,729

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 235

KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 186

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., et al. (2021) · Breast Cancer Research and Treatment

HER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology

Cited by 22